UNSPSC 51241250: Motretinide

This classification denotes a retinoic acid agent with the molecular formula C23H31NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W786807KL1, chemically known as 2,4,6,8-nonatetraenamide, n-ethyl-9- (4-methoxy-2,3, 6-trimethylphenyl)-3,7-dimethyl-, (all-e)- but generally known as motretinide, which bears US NIH Compound Identifier 41827. European Medicines Agency schedules Motretinide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09077MIG.

UNSPSC 51241250 Motretinide is a Commodity code whose nominal scope—a prescription retinoid pharmaceutical—does not align with the recent state and local procurement activity tagged under it. The two most recent opportunities on record are unrelated to the code's intended product: one solicits liquid aluminum sulfate (alum) for wastewater treatment phosphorus removal, the other medical aid supplies including bandages, antiseptic sprays, and first aid kits for a fire rescue department. Neither purchase falls within pharmaceutical or dermatological therapeutics. The mismatch suggests that either the code has been misapplied in these solicitations or the tagging system does not reflect actual procurement intent under this code. State and local governments may be applying this code incorrectly to unrelated chemical and medical supply categories.

The City of Austin issued IFB 2200 CSH1061 on July 27, 2026 for approximately 179,200 gallons annually of NSF-approved liquid aluminum sulfate at 47%-49% concentration, with bids due August 25, 2026; the procurement includes Austin local business and small business preference discounts of 3% to 5% depending on bid size. The City of Tampa issued ITB 25-P-00157 in April 2026 for fire rescue medical supplies including antiseptic sprays, hydrogen peroxide, bandages, and first aid kits, with a total department budget of $100,000 and set-aside provisions for City-certified Small Local Business Enterprises and Underutilized Woman and Minority Owned Business Enterprises offering 5% bid discounts. Given the absence of motretinoid-related opportunities in the recent record and the clear mismatch between the code's pharmaceutical scope and the chemical and medical supply purchases tagged to it, this code shows no relevant recent activity for firms pursuing pharmaceutical procurement contracts with state and local governments.